Any Condition Requiring Surgical Treatment Via ColectomyNCT02044770
ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy
An observational study of Any Condition Requiring Surgical Treatment Via Colectomy, run by Ethicon Endo-Surgery at 3 sites in United States.
Trial summary
The primary objective of this clinical study is to describe the initial clinical experience with ENSEAL® G2 Articulating Tissue Sealer in laparoscopic colectomy, quantifying and/or qualifying how its articulation feature enables optimization of vessel sealing through improved access, approach, and visibility. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Any Condition Requiring Surgical Treatment Via Colectomy
- How many people
- 29 participants
- Where
- 3 sitesUnited States
- Study dates
- Jan 2014to Jun 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult participants (age ≥ 18 and < 80 years of age, on the day of the procedure), scheduled to undergo a planned colectomy, anticipated to be performed laparoscopically
Who may be able to join
- Adult participants (age ≥ 18 and < 80 years of age, on the day of the procedure
- Scheduled to undergo one of the following planned colectomies, anticipated to be performed laparoscopically:
- Right colectomy; b. Left hemicolectomy; c. Transverse colectomy; d. Sigmoidectomy; e. Total colectomy; or f. Subtotal colectomy. f. Subtotal colectomy.
Who cannot join
- Unable or unwilling to sign the study informed consent form;
- Previous colectomy and/or proctectomy;
- Anticipated combinations of laparoscopic colectomy and low anterior resection, except in cases in which the lower anterior resection is intended to be done with an energy device other than the ENSEAL® G2 Articulating Tissue Sealer;
- Any previous major surgery of the colon that, in the opinion of the surgeon, may increase the risk of intraoperative conversion to open surgery;
- Surgery planned to be performed using a single port;
- Surgery planned to be performed with a hand-assisted device;
- Requiring emergency surgery;
- Likely to require an energy tissue sealer/dissector with a shaft larger than 35cm during surgery;
Trial locations and contacts
3 sites in 1 country.
United States3 sites
The Christ Hospital
Cincinnati, Ohio, 45219
Franciscan St. Francis Health
Indianapolis, Indiana, 46237
Jersey Shore University medical Center
Neptune City, New Jersey, 07753
About this study
Official title: Initial Clinical Experience With the ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy
The primary objective of this clinical study is to describe the initial clinical experience with ENSEAL® G2 Articulating Tissue Sealer in laparoscopic colectomy, quantifying and/or qualifying how its articulation feature enables optimization of vessel sealing through improved access, approach, and visibility. This is an observational study of device usage being conducted to report initial experience with the ENSEAL ART device. It is not intended as hypothesis testing.
Read the detailed description
The ENSEAL® G2 Tissue Sealer is a sterile, single-patient use surgical instrument used to coagulate and transect vessels up to and including 7mm in diameter and tissue and/or vascular bundles. In preclinical research using ENSEAL tissue sealers, burst pressures were 51% higher for perpendicularly sealed vessels than for angled seals (p<0.001) and the seal length was the primary variable in determining burst pressure (Voegele AC, 2013). These results suggest that the strongest possible seal may be obtained when vessels are approached perpendicularly and not at an angle.
However, desired angles for vessel sealing cannot always be obtained in the surgical field, especially in laparoscopic surgery due mostly to the fixed nature of the abdominal wall cannulas and the lack of adequate articulating hemostatic tools.
Since strong vessel seals are important for adequate homeostasis, the value of an articulating vessel-sealing device primarily resides in its ability to maneuver around corners and behind structures in confined spaces. An articulating vessel-sealing device would maximize the ability to approach vessels or bundles in a perpendicular manner to provide greater seal strength.
ENSEAL ART is the first articulating advanced bipolar device that can facilitate laparoscopic surgery through a 5mm port. The instrument shaft, can achieve up to 110 degrees of articulation (which improves the visibility of the tip of the device's jaw) to gain access to tissue in challenging anatomy, especially in deep/tight spaces, and facilitate additional angles to transect and seal tissue, vessels, and vascular bundles.
The articulation feature and improved ergonomics of the ENSEAL ART may provide the ability to maneuver around corners and behind structures, while making it easier to capture the full vessel in a single bite. These features may lead to a reduction of the number of ports, the instrument exchanges between ports, the need to pass the energy device to an assistant, and the number of times the surgical table tilt has to be changed during certain laparoscopic surgical procedures (e.g., colectomy).
This study focuses primarily in reporting initial user-centered interactions with the ENSEAL ART device. The users of the device will be board-certified colorectal surgeons, who will use it in an actual clinical setting (i.e., laparoscopic colectomies).
After obtaining Institutional Review Board approval, the study sites will begin recruitment of study participants.
At each of the participating study sites, 8 to 14 participants will undergo a laparoscopic colectomy using the ENSEAL ART for vessel dissection and sealing, according to the institution's standard approach.
Video recordings from the laparoscope and external cameras will capture all device activations completed with the ENSEAL ART device using articulation vs. straight (without articulating). After each surgical case, PIs will complete a survey related to the perceived advantages of the articulating features of ENSEAL ART in the context of their experience using non-articulation tissue sealers. PIs will also complete an assessment (using a validated tool) of the perceived workload of the use of the ENSEAL ART device.
The digital video recording of the surgical procedure will be evaluated by a consultancy group - Design Science Consulting Inc. (Philadelphia, PA), specializing in the conduct of field research of the variables pre-established by the protocol. Design Science is a third party reviewer, not associated with any of the study sites.
Subject-related data to be collected is limited to age, gender, diagnosis, Medical History, and adverse events associated to the use of the device.
- Keywords
- laparoscopic, colectomy, ENSEAL
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of articulated activations
Number of device activations while the device is articulated
Measured: Intraoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2014 (estimated)
- Study startJan 2014
- Primary completionJun 2014
- Study completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Any Condition Requiring Surgical Treatment Via ColectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ethicon Endo-Surgery
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02044770
- Sponsor's protocol ID
- ENG 13-001
- Status last verified
- Sep 2014
- First submitted
- 22 Jan 2014
- Last updated
- 29 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Glenn S. Parker MD, Ben M. Tsai MD, Dipen C. Maun MD, Janice F. Rafferty MD, Michael J. Stamos MD, Edward G. Chekan MD, Michael Schwiers, and Mario Gutierrez (2015)
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Initial Clinical Experience With the ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy
- ClinicalTrials.gov ID
- NCT02044770
- Acronym / sponsor ID
- ENG 13-001
- Keywords
- laparoscopic, colectomy, ENSEAL
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Ethicon Endo-SurgeryIndustry (pharma, biotech, devices)
- Study start
- Jan 2014
- Primary completion
- Jun 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 24 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this clinical study is to describe the initial clinical experience with ENSEAL® G2 Articulating Tissue Sealer in laparoscopic colectomy, quantifying and/or qualifying how its articulation feature enables optimization of vessel sealing through improved access, approach, and visibility. This is an observational study of device usage being conducted to report initial experience with the ENSEAL ART device. It is not intended as hypothesis testing.
Detailed description
The ENSEAL® G2 Tissue Sealer is a sterile, single-patient use surgical instrument used to coagulate and transect vessels up to and including 7mm in diameter and tissue and/or vascular bundles. In preclinical research using ENSEAL tissue sealers, burst pressures were 51% higher for perpendicularly sealed vessels than for angled seals (p<0.001) and the seal length was the primary variable in determining burst pressure (Voegele AC, 2013). These results suggest that the strongest possible seal may be obtained when vessels are approached perpendicularly and not at an angle.
However, desired angles for vessel sealing cannot always be obtained in the surgical field, especially in laparoscopic surgery due mostly to the fixed nature of the abdominal wall cannulas and the lack of adequate articulating hemostatic tools.
Since strong vessel seals are important for adequate homeostasis, the value of an articulating vessel-sealing device primarily resides in its ability to maneuver around corners and behind structures in confined spaces. An articulating vessel-sealing device would maximize the ability to approach vessels or bundles in a perpendicular manner to provide greater seal strength.
ENSEAL ART is the first articulating advanced bipolar device that can facilitate laparoscopic surgery through a 5mm port. The instrument shaft, can achieve up to 110 degrees of articulation (which improves the visibility of the tip of the device's jaw) to gain access to tissue in challenging anatomy, especially in deep/tight spaces, and facilitate additional angles to transect and seal tissue, vessels, and vascular bundles.
The articulation feature and improved ergonomics of the ENSEAL ART may provide the ability to maneuver around corners and behind structures, while making it easier to capture the full vessel in a single bite. These features may lead to a reduction of the number of ports, the instrument exchanges between ports, the need to pass the energy device to an assistant, and the number of times the surgical table tilt has to be changed during certain laparoscopic surgical procedures (e.g., colectomy).
This study focuses primarily in reporting initial user-centered interactions with the ENSEAL ART device. The users of the device will be board-certified colorectal surgeons, who will use it in an actual clinical setting (i.e., laparoscopic colectomies).
After obtaining Institutional Review Board approval, the study sites will begin recruitment of study participants.
At each of the participating study sites, 8 to 14 participants will undergo a laparoscopic colectomy using the ENSEAL ART for vessel dissection and sealing, according to the institution's standard approach.
Video recordings from the laparoscope and external cameras will capture all device activations completed with the ENSEAL ART device using articulation vs. straight (without articulating). After each surgical case, PIs will complete a survey related to the perceived advantages of the articulating features of ENSEAL ART in the context of their experience using non-articulation tissue sealers. PIs will also complete an assessment (using a validated tool) of the perceived workload of the use of the ENSEAL ART device.
The digital video recording of the surgical procedure will be evaluated by a consultancy group - Design Science Consulting Inc. (Philadelphia, PA), specializing in the conduct of field research of the variables pre-established by the protocol. Design Science is a third party reviewer, not associated with any of the study sites.
Subject-related data to be collected is limited to age, gender, diagnosis, Medical History, and adverse events associated to the use of the device.
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult participants (age ≥ 18 and < 80 years of age, on the day of the procedure), scheduled to undergo a planned colectomy, anticipated to be performed laparoscopically
Key inclusion criteria (3 listed)
- Adult participants (age ≥ 18 and < 80 years of age, on the day of the procedure
- Scheduled to undergo one of the following planned colectomies, anticipated to be performed laparoscopically:
Key exclusion criteria (8 listed)
- Unable or unwilling to sign the study informed consent form;
- Previous colectomy and/or proctectomy;
- Anticipated combinations of laparoscopic colectomy and low anterior resection, except in cases in which the lower anterior resection is intended to be done with an energy device other than the ENSEAL® G2 Articulating Tissue Sealer;
- Any previous major surgery of the colon that, in the opinion of the surgeon, may increase the risk of intraoperative conversion to open surgery;
- Surgery planned to be performed using a single port;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of articulated activations
Time frame: Intraoperative
Number of device activations while the device is articulated
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2015.
- Results publicationGlenn S. Parker MD, Ben M. Tsai MD, Dipen C. Maun MD, Janice F. Rafferty MD, Michael J. Stamos MD, Edward G. Chekan MD, Michael Schwiers, and Mario Gutierrez (2015)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Any Condition Requiring Surgical Treatment Via Colectomy, run by Ethicon Endo-Surgery at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of articulated activations (time frame: Intraoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02044770, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2015.